Literature DB >> 86997

The attenuation of delta 9-tetrahydrocannabinol and morphine of the quasi-morphine withdrawal syndrome in rats.

S G Zaluzny, G B Chesher, D M Jackson, R Malor.   

Abstract

The effect of delta 9-tetrahydrocannabinol (THC), morphine, haloperidol and chlordiazepoxide on the exhibition of the signs of the quasi-morphine withdrawal syndrome was studied in rats. In preliminary studies approximately equi-sedative doses of these drugs were chosen. Morphine and THC produced a very similar degree of suppression of the signs of the quasi-morphine withdrawal, but unlike morphine, the effects of THC were not reversed by the narcotic antagonist, naloxone. The dopamine receptor antagonist, haloperidol, produced a moderate suppression of the withdrawal syndrome and chlordiazepoxide was without significant effect. It is concluded that THC is of very similar potency to morphine in suppressing the quasi-morphine withdrawal syndrome, but its activity in this regard does not appear to be dependent upon the availability of opiate or dopamine receptors, nor is it due to sedation alone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86997     DOI: 10.1007/BF00426738

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol.

Authors:  B Hine; E Friedman; M Torrelio; S Gershon
Journal:  Science       Date:  1975-02-07       Impact factor: 47.728

2.  Morphine receptors as regulators of adenylate cyclase activity.

Authors:  S K Sharma; M Nirenberg; W A Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

3.  Morphine abstinence is associated with increased brain cyclic AMP.

Authors:  H O Collier; D L Francis
Journal:  Nature       Date:  1975-05-08       Impact factor: 49.962

4.  Morphone abstinence and quasi-abstinence effects after phosphodiesterase inhibitors and naloxone.

Authors:  D L Francis; A C Roy; H O Collier
Journal:  Life Sci       Date:  1975-06-15       Impact factor: 5.037

5.  Tetrahydrocannabinol-attenuated abstinence and induced rotation in morphine-dependent rats: possible involvement of dopamine.

Authors:  B Hine; E Friedman; M Torrelio; S Gershon
Journal:  Neuropharmacology       Date:  1975-08       Impact factor: 5.250

6.  Proceedings: Stereospecific suppression by opiates of the quasi-morphine abstinence syndrome elicited by 3-isobutyl-l-methylxanthine (IBMX).

Authors:  H O Collier; D L Francis
Journal:  Br J Pharmacol       Date:  1976-03       Impact factor: 8.739

7.  Quasi morphine-abstinence syndrome.

Authors:  H O Collier; D L Francis; G Henderson; C Schneider
Journal:  Nature       Date:  1974-05-31       Impact factor: 49.962

8.  A comparison of haloperidol with methadone in blocking heroin-withdrawal symptoms. A pilot study.

Authors:  J Karkalas; H Lal
Journal:  Int Pharmacopsychiatry       Date:  1973

9.  Morphine-like drugs inhibit the stimulation of E prostaglandins of cyclic AMP formation by rat brain homogenate.

Authors:  H O Collier; A C Roy
Journal:  Nature       Date:  1974-03-01       Impact factor: 49.962

10.  Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC.

Authors:  B Hine; M Torrelio; S Gershon
Journal:  Psychopharmacol Commun       Date:  1975
View more
  3 in total

1.  Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat.

Authors:  B Hine
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Effects of single and repeated daily injections of morphine, clonidine, and l-nantradol on avoidance responding of rats.

Authors:  J B Smith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 3.  Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature.

Authors:  Kiri L Wills; Linda A Parker
Journal:  Front Pharmacol       Date:  2016-06-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.